Parsaclisib in Patients With Relapsed or Refractory Follicular Lymphoma

Category Primary study
Registry of TrialsClinicalTrials.gov
Year 2023
A Phase Ib/III, Multicenter, double-blinded study of Parsaclisib, a PI3Kδ Inhibitor, in Patients with Relapsed or Refractory Follicular Lymphoma
Epistemonikos ID: cfcac672f50fd7d85c591296f9d7e2a446b0b27b
First added on: Feb 19, 2024